SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): August 2, 2004
ARIAD PHARMACEUTICALS, INC.
---------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21696 22-3106987
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
In its press release dated August 2, 2004, included as Exhibit 99.1
hereto, ARIAD Pharmaceuticals, Inc. updated the status of its clinical
and preclinical programs under the headings, "Update on AP23573
Clinical Program" and "Update on Preclinical Programs." The Company
hereby incorporates such information by reference into Item 5 of this
Current Report on Form 8-K.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated August 2, 2004.
The portions of the Press Release incorporated by reference into Item
5 of this Current Report on Form 8-K are being filed pursuant to Item
5. The remaining portions of the Press Release are being furnished
pursuant to Item 12 of this Current Report on Form 8-K and shall not
be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that Section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the
Exchange Act.
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 2, 2004, ARIAD Pharmaceuticals, Inc. announced its financial
results for the three months ended June 30, 2004. A copy of the Press
Release is furnished pursuant to this Item 12 as Exhibit 99.1 to this
Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Edward M. Fitzgerald
------------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: August 2, 2004
2
EXHIBIT INDEX
-------------
Exhibit
Number Description Sequential Page Number
- ------- ----------- ----------------------
99.1 The Registrant's Press Release dated 4
August 2, 2004.
3